"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
| Descriptor ID |
D014614
|
| MeSH Number(s) |
D12.776.828.868 D20.215.894.865 D23.050.865
|
| Concept/Terms |
Vaccines, Synthetic- Vaccines, Synthetic
- Synthetic Vaccines
- Synthetic Immunogens
- Immunogens, Synthetic
Molecular Vaccines- Molecular Vaccines
- Vaccines, Molecular
- Vaccines, Chemical
- Chemical Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".
This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 6 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 3 | 3 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.
-
Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines. J Virol. 2026 Jun 23; 100(6):e0031726.
-
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. Front Immunol. 2026; 17:1779435.
-
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia. J Infect. 2026 Apr; 92(4):106727.
-
Impact of infection timing before vaccination on the effectiveness of COVID-19 mRNA vaccine in healthcare workers. Microbiol Spectr. 2025 12 02; 13(12):e0128825.
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2025 02 06; 46:126668.
-
Intestinal Helminth Infection Impairs Oral and Parenteral Vaccine Efficacy. J Immunol. 2023 08 01; 211(3):389-402.
-
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat Rev Immunol. 2023 03; 23(3):135-136.
-
Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland. Nat Commun. 2022 09 28; 13(1):5701.